E-learning: MRD Negativity in Multiple Myeloma (MM) | healthbook

MRD Negativity in Multiple Myeloma (MM)

Share:

Author:

Prof. Dr Christoph Driessen

Chief Physician, Clinic for Medical Oncology and Hematology, Kantonsspital St.Gallen (KSSG)

2 cme credits

granted by SGH, SGMO

About Multiple Myeloma (MM)
Introduction to MM
Incidence and prevalence of MM
The prognostic significance of minimal residual disease (MRD)
Evolution of MGUS to MM
Pathogenesis of MM
Types of MM therapy
Risk factors
Diagnosis
Stages and grading
MRD methods and sensitivity
MRD negativity-based treatment
Treatment Landscape For MM
Current treatment guidelines for MM
Newly diagnosed multiple myeloma (NDMM)
Relapsed/refractory multiple myeloma (RRMM)
Summary Of Clinical Trials Investigating MRD Status
MRD status as a surrogate endpoint for PFS
Transplant-eligible newly diagnosed MM
Transplant-ineligible newly diagnosed MM
Relapsed/refractory (RR) MM
Prognostic value of MRD negativity by depth of response
Balancing disease status and the immune environment in MM
Future approaches and other emerging treatment strategies
Summary/Take Home Messages